Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis.

backgroundTrimetazidine is an anti-ischemic agent with anti-oxidant activity. This study sought to evaluate the impact of oral trimetazidine on extent of myocardial damage in diabetic patients who were presented with anterior wall ST-segment elevation myocardial infarction (STEMI).

methodsOne hundred patients were prospectively enrolled, and then randomly assigned to receive oral trimetazidine (70 mg then 35mg bid) (group A, 50 patients) or placebo (group B, 50 patients), starting before thrombolysis. Serum creatine kinase-T and MB (CK-T and CK-MB) were measured serially. Degree of ST-segment resolution was recorded after 90 minutes. Left ventricle ejection fraction (LVEF) was assessed at baseline and after 6 months. Adverse events were recorded after thrombolysis and 6 months later.

resultsMean age of the study cohort was 59.05 ± 3.8 years (males: 60%). After 24 hours, 45 (90%) patients in group A vs. 10 (20%) patients in group B showed peaking of CK-T and CK-MB levels (P < 0.05). Both biomarkers' levels were significantly higher in the placebo group at different sampling times. Complete resolution of ST-segment elevation was recorded in 35 (70%) patients in group A vs. 18 (36%) patients in group B (P < 0.05). Six months later, group A showed higher LVEF and fewer cardiac adverse events (P < 0.05).

conclusionIn diabetic patients receiving thrombolytic therapy for anterior wall STEMI, oral trimetazidine dosing was associated with less myocardial damage, earlier successful reperfusion, improvement of LVEF and less cardiac adverse events.